BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
复制标题
DOI：
10.1038/s41586-021-03693-y
复制
发表时间：
2021-06-10
期刊：
影响因子：
64.8
通讯作者：
Shi, Pei-Yong
中科院分区：
文献类型：
--
作者：
Liu, Jianying;Liu, Yang;Shi, Pei-Yong
严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）在世界各地继续演变，产生了令人担忧的新变体，因为它们可能改变其传播性、致病性以及疫苗和治疗剂的覆盖范围（1-5）。本研究表明，在20名人类志愿者接种第二剂BNT162b2疫苗后两周或四周采集的血清样本，中和了具有美国- wa1 /2020遗传背景（2020年1月分离的一种病毒株）的工程SARS-CoV-2，以及来自最近发现的B.1.617.1、B.1.617.2、B.1.618（所有这些病毒均首次在印度发现）或B.1.525（首次在尼日利亚发现）谱系的刺突糖蛋白。对变异病毒（特别是B.1.617.1变异）的几何平均空斑减少中和效价似乎低于对USA-WA1/2020病毒的效价，但所有检测的血清都至少以1:40的效价中和变异病毒。变异毒株对BNT162b2疫苗引起的中和的易感性支持将大规模免疫作为结束2019冠状病毒病（COVID-19）全球大流行的中心战略。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents(1-5). Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses-particularly the B.1.617.1 variant-seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally.